Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment data IMVT-1402 development is progressing...
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business...
The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant , Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigating whether Immunovant’s...
First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patients Of 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response,...
NEW YORK and NEW ORLEANS , Aug. 29, 2025 /PRNewswire/ -- The law firm of Kahn Swick & Foti, LLC ("KSF") has commenced an investigation into Immunovant , Inc. (NasdaqGS: IMVT)...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immunovant, Inc. (“Immunovant” or “the Company”)...
The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant , Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigating whether Immunovant’s...
Immunovant, Inc. IMVT reported first-quarter fiscal 2026 adjusted net loss of 60 cents per share, narrower than the Zacks Consensus Estimate of a loss of 69 cents. In the year-ago quarter, the company...
Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren’s disease (SjD), both in June 2025 All other...